Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=start_date
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=start_date", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=start_date", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=start_date", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=start_date" }, "data": [ { "type": "Grant", "id": "15513", "attributes": { "award_id": "1F31AI181616-01", "title": "HIV/Mycobacterium tuberculosis co-infection: cellular dynamics in granulomas", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 27645, "first_name": "Leshawndra Nyrae", "last_name": "Price", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-12-01", "end_date": "2027-11-30", "award_amount": 53974, "principal_investigator": { "id": 32056, "first_name": "Jessica Marie", "last_name": "Medrano", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Tuberculosis (TB), a respiratory disease caused by the bacterium Mycobacterium tuberculosis (Mtb), is one of the leading causes of death by a single infectious agent, second only to SARS-CoV-2. In 2020, Mtb infected 10 million and killed 1.5 million people worldwide. 5-10% of those infected with Mtb will go on to develop active disease, and the most important risk factor is co-infection with human immunodeficiency virus (HIV). The resurgence of TB is tied to the emergence of the HIV epidemic, and one-third of HIV-associated deaths are due to TB. Development of most opportunistic infections after HIV infection is correlated with the degree of HIV- driven depletion of CD4+ T cells in the blood. Antiretroviral therapy, which prevents ongoing viral replication and CD4+ T cell depletion, has been revolutionary in managing HIV but is not curative. Importantly, people living with HIV remain more likely than those HIV-naïve to develop TB despite effective ART and normalized CD4+ T cell count. Immune dysregulation during HIV/Mtb co-infection is clearly more complex than simply CD4+ T cell depletion but remains incompletely understood. The hallmark of Mtb infection is the formation of granulomas: organized structures of immune cells that develop in response to Mtb-infected macrophages. Granulomas are critical for bacterial containment, and each is independent from others within a host. The function of a granuloma is closely tied to its spatial architecture, which determines cell-cell interactions necessary for function of immune cells. Outcomes of infection are likely dependent on the cumulative success or failure of individual granulomas in a host. I hypothesize that chronic SIV infection at the time of Mtb co-infection leads to aberrant macrophage and CD8+ T cell function within lung granulomas that favors microenvironments permissive to greater bacterial burden. Our laboratory’s established non-human primate (NHP) model of co-infection recapitulates human TB disease and uses simian immunodeficiency virus (SIV) as a surrogate for HIV. I propose to leverage this model to understand how SIV changes the immune microenvironment of granulomas during co-infection using multidisciplinary ex vivo and in vitro assays in combination with ex vivo imaging and systems immunology. In Aim 1, I will assess SIV infection of macrophages in granulomas and determine alterations in macrophage cell state. In Aim 2, I will determine how SIV drives altered CD8+ T cell function in granulomas. Results from the proposed aims will shed light on the complex immune dynamics important during SIV/Mtb co-infection, which will inform vaccine and therapeutics development.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15515", "attributes": { "award_id": "1R01NS136202-01A1", "title": "Investigating Mechanisms of Neurological Post Acute Sequelae of SARS CoV2 Using Quantitative Multiparametric In-Vivo and Ex-Vivo MRI", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 9314, "first_name": "LUMY", "last_name": "Sawaki-Adams", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-12-01", "end_date": "2029-11-30", "award_amount": 634622, "principal_investigator": { "id": 21207, "first_name": "Priti", "last_name": "Balchandani", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 32058, "first_name": "Alan C", "last_name": "Seifert", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "More than half of individuals infected with COVID-19 continue to experience debilitating symptoms beyond the initial phase of their infection – a syndrome that is now known as Post-Acute Sequelae of COVID-19 (PASC). When neurological manifestations such as altered smell or taste, post-exertional malaise, “brain fog” (impaired cognition, executive function, and memory), fatigue, dizziness, abnormal movements, headache, sleep disturbances, mood disorders, and/or dysautonomia, are concerned, this syndrome is termed neuroPASC. Knowledge of the specific mechanisms by which SARS-CoV-2 causes damage to the brain and brainstem is vitally important to inform clinical treatment of patients suffering from neuroPASC, but at this point, our knowledge is severely lacking. We hypothesize that SARS-CoV-2 infection causes immune-mediated injury to the neurovascular endothelium, causing microhemorrhages, microinfarctions, and vascular leakage followed by secondary damage to the neural parenchyma due to immune-mediated inflammation in response to breakdown of the blood-brain barrier. The consequences of this tissue injury will manifest as a specific spatiotemporal distribution of neuroimaging findings on in vivo MRI, associated with neurological signs and symptoms and markers of inflammation. The results of this project will rigorously confirm the mechanisms by which SARS-CoV- 2 infection causes tissue damage that leads to neuroPASC, and by leveraging ex vivo MRI to link in vivo neuroimaging findings on a clinically translatable MRI protocol and the presence and temporal evolution of neurological signs and symptoms to a detailed histopathological explanation of the underlying mechanisms by which neural tissue is damaged in neuroPASC, this project will establish a foundation of knowledge for targeted interventions and provide protocols and biomarkers to evaluate the efficacy of those interventions. The specific aims of this project are as follows: Aim 1: we will acquire high-resolution, multi-contrast, quantitative ex vivo MRI and detailed histological datasets in hemibrains from 25 neuroPASC-positive decedents and 15 neuroPASC- negative control decedents who recovered from their acute course of COVID-19 without persistent neurological sequelae. We will compare frequencies of MRI and histological findings in neuroPASC and controls throughout the regions of the brain and brainstem implicated by prominent symptoms to confirm the aforementioned mechanistic hypothesis, and also identify additional spatial patterns of neuroPASC-related abnormalities through data-driven analyses. Aim 2: we will apply an in vivo 7 T structural, vascular, perfusion, and diffusion MRI protocol and perform neuropsychological testing and quantification of blood inflammatory markers in 60 neuroPASC-positive patients at two time points, and 60 neuroPASC-negative control subjects at a single time point. We will analyze the spatial distribution of neuroimaging findings and their evolution over time as neuroPASC symptoms abate to support a hypothesis that resolution of symptoms is closely temporally linked with resolution of specific spatial distributions of neuroimaging findings.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15661", "attributes": { "award_id": "2509179", "title": "Conference: Building Teams to Build Better Epidemiological Models: Balancing Participation from Mathematical and Social, Behavioral, and Economic Sciences", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Unknown", "MSPA-INTERDISCIPLINARY" ], "program_reference_codes": [], "program_officials": [ { "id": 1173, "first_name": "Joseph", "last_name": "Whitmeyer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-12-01", "end_date": null, "award_amount": 29940, "principal_investigator": { "id": 32169, "first_name": "Dana", "last_name": "Pasquale", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "This award will support two separate one-day virtual conferences entitled “Building Teams to Build Better Epidemiological Models: Balancing Participation from Mathematical and Social, Behavioral, and Economic Sciences” (https://sites.duke.edu/betterepidemiologicalmodelsconference/), to be held in January 2025. In a crisis such as the COVID-19 pandemic, mathematical models played their role in designing, developing, deploying, and evaluating public health strategies with different levels of success. Still, all were confronted with prioritizing public health or economic viability. To frame a sound pandemic response strategy, mathematical models are primary tools that must incorporate behavioral components and frameworks to be more efficient and useful for public health policy interventions and the evaluation of the economic impact of such measures. The COVID-19 pandemic highlights the need to develop mathematical methodologies, new techniques, and innovative approaches designed to incorporate the new paradigm of behavioral dynamics into the transmission dynamics of human diseases. Multidisciplinary teams are needed to innovate new mathematical methodologies which incorporate human behavioral and social dynamics. This award will be used to support a conference to bring together mathematical and social / behavioral / economic scientists to develop improved epidemiological models which can protect both public health and the economy. Applicants will be selected to balance these research areas, with attention given during the selection process to ensure that women and members of underrepresented groups are fully considered with an eye to broadening participation. The standard framework for the mathematical modeling of infectious diseases is the basic Kermack-McKendrick model, a compartmental model framed in ordinary differential equations and their extensions to stochastic and hybrid models. Mixing is a random process in this framework, and this characteristic has pervaded in models for prediction and forecasting and is one, but not unique, of the most challenging and important topics in modeling infectious diseases: how to modify the basic assumption of the homogeneous population in the model to incorporate significant behavioral effects robustly and effectively. For example, there have been several efforts in literature to integrate behavior; one of them is the one that assumes that agents that interact during the transmission of the disease are rational, i.e., the individuals behave in a way consistent with a rational evaluation of risks. This model type is based on economic thinking in which costs and benefits are balanced, where there is a trade-off that rational agents resolve. The problem in epidemiology is that many of the actions of natural agents during an epidemic do not adapt to this hypothesis; therefore, applying this type of modeling requires the development of innovative ideas, alternative conceptual frameworks, and new mathematical techniques and methodologies. Scientific teams which can innovate and parameterize mathematical models which are tractable, represent an analogue of human behavior and transmission, work across a variety of domains and settings, and can be used to test interventions are needed. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15662", "attributes": { "award_id": "2401975", "title": "Excellence in Research: a PEC-AbP Dual Signal Amplification Method and its Mechanistic Study of Signal Transduction for DNA Sensing", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Unknown", "HBCU-EiR - HBCU-Excellence in" ], "program_reference_codes": [], "program_officials": [ { "id": 961, "first_name": "Aleksandr", "last_name": "Simonian", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-12-01", "end_date": null, "award_amount": 599991, "principal_investigator": { "id": 32171, "first_name": "Peng", "last_name": "He", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 32170, "first_name": "Jianjun", "last_name": "Wei", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 708, "ror": "", "name": "North Carolina Agricultural & Technical State University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "DNA sensing techniques have been widely applied in daily life such as medical diagnosis, biowarfare defense, forensic science, and environmental monitoring, and were significantly promoted during the past pandemic, e.g., reverse transcription polymerase chain reaction (RT-PCR) test for COVID-19. Rapid DNA detection with high sensitivity, specificity, and accuracy is in high demand, however limited by signal readout. This project is aimed at developing an innovative dual signal amplification method by integrating two different signal amplification methods, i.e., materials science- and optical-based. The research goals are to strengthen signal readouts and build field-friendly DNA sensors that are amenable to point-of-need applications with ultrasensitivity. The discovery of fundamental science and transformative technology will potentially enable a reliable multiplexed high-throughput DNA analysis platform that may greatly benefit health care in society and facilitate research and applications in biomedical and life science. The scientific learning of this interdisciplinary research performed at the HBCU (NC A&T) and MSI (UNC Greensboro) will advance sensing mechanism understanding, instruct and train students especially underrepresented students, in research and education, and engage K-12 STEM educators and students in science. Genetic information with or without variation coded within nucleic acids, indicating an illness or health outcome, is termed a nucleic acid biomarker, thus plays a crucial role in precision medicine. Sensitive and selective detection of nucleic acid biomarkers with rapid signal amplification is the key for early screening and diagnosis of human diseases. This project is aimed at developing an innovative dual signal amplification method and understanding the signal transduction mechanism for enhanced DNA sensing. The work is built on the seamless integration between amplification-by-polymerization (AbP) in DNA sensing for optical clarity change on surface based on effective mass growth upon DNA recognition and in-planar metallic film nanoarrays for plasmon-exciton coupling (PEC) optical enhancement. The research will be conducted in three stages to (1) fully explore the potential of the AbP-PEC dual signal amplification platform, (2) investigate the fundamental mechanism of the amplified signal transduction pertaining to the AbP-produced film thickness and plasmonic nanoslit structure, and (3) optimize the AbP-PEC platform for a portable DNA sensor in point-of-care diagnostics. The outcome may be transformative towards a multiplexed, rapid, highly sensitive, visible (by naked eyes) analysis of DNA in biofluids. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15663", "attributes": { "award_id": "2449747", "title": "I-Corps: Translation Potential of Safe Biomedical Perfusion Technologies", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Technology, Innovation and Partnerships (TIP)", "I-Corps" ], "program_reference_codes": [], "program_officials": [ { "id": 602, "first_name": "Ruth", "last_name": "Shuman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-12-01", "end_date": null, "award_amount": 50000, "principal_investigator": { "id": 3094, "first_name": "Hosam", "last_name": "Fathy", "orcid": "https://orcid.org/0000-0002-4714-2466", "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 297, "ror": "https://ror.org/047s2c258", "name": "University of Maryland, College Park", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 297, "ror": "https://ror.org/047s2c258", "name": "University of Maryland, College Park", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "The broader impact of this I-Corps project is the development of a safety control system for biomedical perfusion applications. Perfusion involves the circulation of an external fluid through a body compartment, often using surgically inserted catheters. Currently, multiple safety risks exist during perfusion procedures, including the risk of blood flow occlusion during high-pressure perfusion as well as the risk of tissue damage resulting from high perfusion and/or drainage flowrates. Many existing and emerging biomedical applications involve the use of perfusion, especially through the abdominal cavity. These applications include peritoneal dialysis, hyperthermic intraperitoneal chemotherapy (HIPEC), and peritoneal oxygenation. This technology is designed to address the safety risks, which may have the potential to improve the safety of biomedical perfusion and potentially improve patients’ outcomes. This I-Corps project utilizes experiential learning coupled with a first-hand investigation of the industry ecosystem to assess the translation potential of a control algorithm for the safe perfusion of oxygenated perfluorocarbons through the peritoneal cavity. Perfusion plays a critical role in both existing life-saving biomedical interventions (such as peritoneal dialysis, hyperthermic intra-peritoneal chemotherapy, and extra-corporeal membrane oxygenation) as well as emerging interventions (such as peritoneal oxygenation). This technology utilizes perfusion flowrate, pressure, and volume sensors to estimate and manage multiple perfusion safety hazards simultaneously. These technologies were developed as an emerging medical intervention where oxygen-rich liquids are perfused through patients’ abdomens to enable oxygen transport into the bloodstream via diffusion. This technology has the potential to allow the abdomen to serve as a “third lung”, particularly for patients with respiratory failure due to ailments such as COVID-19. The solution will improve the safety during peritoneal oxygenation and more broadly during any biomedical perfusion application. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15664", "attributes": { "award_id": "2438012", "title": "I-Corps: Translation Potential of an Enhanced Fluorescence-based Diagnostic Technology for the Detection of Lyme Disease", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Technology, Innovation and Partnerships (TIP)", "I-Corps" ], "program_reference_codes": [], "program_officials": [ { "id": 31316, "first_name": "Jaime A.", "last_name": "Camelio", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-12-01", "end_date": null, "award_amount": 50000, "principal_investigator": { "id": 32172, "first_name": "Nathaniel", "last_name": "Cady", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 571, "ror": "", "name": "SUNY at Albany", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The broader impact of this I-Corps project is the development of an enhanced fluorescence-based diagnostic technology for the detection of antibodies and other biomarkers for disease diagnostics. The base technology has been demonstrated for diagnosing high profile diseases including COVID-19 and Lyme disease. For this I-Corps effort, Lyme disease has been chosen as the beachhead market due to the current diagnostic challenges, and the growing market for fast and accurate Lyme disease diagnostic technologies. The accepted standard for Lyme disease, known as standard two-tiered testing (STTT) is time consuming, requires specialists to run, and can be unreliable, especially for early stages of the disease. This technology has proven to alleviate these pain points, providing rapid and accurate Lyme disease diagnosis, especially for early Lyme disease patients. The platform has also been utilized for detecting RNA-protein and DNA-protein interactions, which potentially broadens its utility for a large number of different disease diagnostic applications, biomarker discovery, and biological / pharmaceutical research applications. The technology may have impact in several clinical and biological research fields. This I-Corps project utilizes experiential learning coupled with a first-hand investigation of the industry ecosystem to assess the translation potential of the technology. This solution is based on the development of a photonics-based Lyme disease diagnostic platform. Lyme disease is the most common vector-borne disease in the United States and, despite advances, remains a considerable diagnostic challenge. Confirmatory diagnosis requires a second test, performed in series, often in batches, and at a centralized laboratory. This delay can lead to considerable morbidity in disseminated Lyme disease. This technology is a low-cost, highly sensitive, fluorescence-based platform, which provides a rapid, easy-to-use, and highly accurate Lyme test that could be used outside traditional clinical laboratories or for more rapid and accurate diagnosis within clinical laboratories. The proof-of-principle research positions the technology as a rapid (<40 minutes total test time) and reliable alternative to traditional Lyme tests, while retaining the full sophistication of a two-tiered testing system. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15511", "attributes": { "award_id": "1K24AI188458-01", "title": "Mentoring translational researchers in perinatal infectious diseases", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 26918, "first_name": "Michelle Marie", "last_name": "Arnold", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-12-04", "end_date": "2029-11-30", "award_amount": 205999, "principal_investigator": { "id": 27211, "first_name": "Stephanie Lina", "last_name": "Gaw", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 768, "ror": "https://ror.org/043mz5j54", "name": "University of California, San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "There has been increasing interest in translational research in perinatal infectious diseases among applicants to medical schools, residency programs, and collaborating subspecialty fellowships (e.g. maternal-fetal medicine, infectious disease, neonatology) recent years. However, the career development pathways for translating this interest into successful academic careers remain poorly defined, with relatively few successful mentors available in academia. The candidate for this K24 Award is an Associate Professor of Maternal-Fetal Medicine who has established a funded research program to investigate the maternal-fetal immune responses against infection in pregnancy, including SARS-CoV-2 and malaria. This research program is based upon strong collaborative relationships with pediatric and adult infectious disease researchers, basic and translational immunologists, and placental biologists. The PI and her collaborators have forged an effective multidisciplinary team and have built substantial research infrastructure to develop longitudinal cohorts of mother/infant dyads from pregnancy, into childhood, and even into the subsequent pregnancy. The recent epidemics of novel Zika virus and SARS-CoV-2 have demonstrated a clear need to understand the complexities of maternal-fetal immune interactions, and the potential for maternal exposures to bridge neonatal and infant immunity. Our current understanding of human maternal-fetal immunity is very limited, and translational studies are comprised largely of descriptive studies of maternal-fetal antibody transfer. The role of the placenta in mediating immune cross-talk between mother and fetus, as well as the impact of in utero exposures on infant immune development need further study. The proposed study will use samples prospectively collected from well-characterized pregnancy cohorts to identify placental mediators of maternal- fetal immune interactions in response to SARS-CoV-2. In addition, this award support exploration into a new area of investigation – the interactions between environmental exposures and susceptibility to infection—which will spawn new projects for mentees. The primary goal of this K24 will be to develop a cohort of young investigators with the skills required to conduct high quality translational research in the field of perinatal infectious diseases. Secondary goals are to encourage their passion for patient-oriented reproductive infectious diseases research and to help them to become successful independent investigators. Trainees will include physician scientists at all levels – maternal-fetal medicine, infectious disease, and neonatology fellows, post-doctoral scholars, residents, and students.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15514", "attributes": { "award_id": "1R01AI188950-01", "title": "Rational design of a unique vaccine for emerging pandemic coronaviruses", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6908, "first_name": "JENNIFER L.", "last_name": "Gordon", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-12-06", "end_date": "2029-11-30", "award_amount": 755225, "principal_investigator": { "id": 9582, "first_name": "Lanying", "last_name": "Du", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 964, "ror": "https://ror.org/03qt6ba18", "name": "Georgia State University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 32057, "first_name": "LIANG", "last_name": "QIAO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1513, "ror": "https://ror.org/04b6x2g63", "name": "Loyola University Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "SARS-CoV-2 has caused the global COVID-19 pandemic. Vaccines against SARS-CoV-2, mostly using spike (S) protein as a target antigen to induce neutralizing antibodies, have been developed at unprecedented speed and several have been approved for use in human. The currently developed vaccines induce neutralizing antibodies and provide protection against SARS-CoV-2 original strain or earlier variants, but they have reduced neutralizing activity or protection against recent variants. Based on the fact that three pandemic coronaviruses (CoVs) have emerged within 20 years, some unknown CoVs with pandemic potential are expected to emerge in the foreseeable future. Therefore, a vaccine is urgently needed to prevent a future emerging CoV. Three CoV outbreaks caused by the three highly pathogenic CoVs (SARS-CoV, SARS-CoV-2 and MERS-CoV) are all from beta-CoVs, in particular, from Sarbecovirus and Merbecovirus lineages, we thus reason that future emerging CoVs causing pandemics may most likely come from these two lineages and that both lineages should be targeted to develop a vaccine to prevent against the future emerging virus. However, we cannot predict the sequences of S protein of future emerging CoV to make a vaccine targeting S to induce neutralizing antibodies. Our prior data showed that a S protein-based vaccine by using ubiquitination and gene rearrangement strategy to enhance its degradation in proteasome induced strong T cell responses, in particular CTLs. This vaccine significantly protected mice against SARS-CoV-2-induced survival and weight loss, and the protection required CD4+ and CD8+ T cells. Thus, we will design CoV vaccines that target the proteins with great homology (i.e., S2, M, and N) from Sarbecoviruses and Merbecoviruses to induce protective T cells. Furthermore, upper respiratory tract tissue-resident memory T cells (TRM) play essential roles in providing immediate protection, and mucosal immunization is the only way to induce upper respiratory tract TRM. Because papillomavirus-like particles (PV- VLPs) induce mucosal immune responses, which serve as a mucosal delivery vector and adjuvant, we hypothesize that PV-VLPs can deliver CoV homologous antigens to nasal-associated lymphoid tissue, and induce respiratory tract TRM for effective protection against Sarbecovirus and Merbecovirus-caused respiratory syndrome and pneumonia. Using Sarbecoviruses and Merbecoviruses as model viruses, this proposal will 1) develop a PV-VLP-based, T cell-inducing mucosal CoV vaccine targeting conserved CoV antigens (S2, M and N) and using gene rearrangement and ubiquitination strategies, 2) determine if the vaccine induces mucosal and systemic immune responses to Sarbecoviruses and Merbecoviruses, in particular, long-term upper respiratory tract TRM, and 3) evaluate vaccine's cross-protective efficacy against infections of Sarbecoviruses and Merbecoviruses in mouse models. We have solid preliminary data, well-established animal models and vaccine platforms, and a strong research team with decades of extensive experience in developing safe and effective CoV vaccines, providing feasibility and basis for the proposed studies.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15525", "attributes": { "award_id": "1K08AI187711-01", "title": "Identifying mechanisms of immune dysregulation via severe pediatric SARS-CoV-2", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 26918, "first_name": "Michelle Marie", "last_name": "Arnold", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-12-15", "end_date": "2029-11-30", "award_amount": 200016, "principal_investigator": { "id": 32066, "first_name": "Aaron", "last_name": "Bodansky", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 768, "ror": "https://ror.org/043mz5j54", "name": "University of California, San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "This proposal presents a five year research career development program focused on the mechanisms by which a dysregulated adaptive immune response to SARS-CoV-2 infection leads particular children to become critically ill. The candidate is currently a Pediatric Critical Care Medicine (PCCM) clinical fellow at the University of California, San Francisco (UCSF) and has been appointed Assistant Professor of Pediatrics at UCSF beginning July 1, 2024. The outlined proposal builds on the candidate's previous research and clinical experience caring for, and studying, children with multisystem inflammatory syndrome in children (MIS-C), a severe and enigmatic post-SARS-CoV-2 inflammatory disease. It integrates the synergistic expertise of co- mentors Joseph DeRisi and Mark Anderson in state-of-the-art functional genomic technologies for immune profiling and mechanisms of autoimmune disease. The proposed experiments and training will position the candidate with a unique set of cross disciplinary skills that will enable his transition to independence as a physician scientist studying mechanisms of immune dysregulation in pediatric critical illness. Immune dysregulation is increasingly recognized as underlying a wide range of critical illness in children. Efforts to treat these conditions are limited by a lack of diagnostic clarity or targeted therapies, underpinned by gaps in knowledge of the specific mechanisms by which infections precipitate immune dysregulation. Previous work studying adults with COVID19 revealed that unrecognized autoantibodies predispose certain individuals to critical illness. However, in part because severe pediatric SARS-CoV-2 related disease is so rare, a detailed mechanistic understanding of what causes certain children to be particularly vulnerable remains lacking. The foundation of this proposal are preliminary studies which leveraged state-of-the-art technologies to identify a set of novel autoantibodies specific to children with MIS-C, and the related discovery of cross-reactive B and T cells between SARS-CoV-2 and the antiviral host protein SNX8. Whether additional novel autoantibodies contribute to a wider range of severe pediatric SARS-CoV-2 related diseases, and how cross-reactive adaptive immune responses lead to MIS-C, are questions addressed in this proposal. The aims are: 1) Define and characterize the autoantibody repertoire in children with severe SARS-CoV-2 disease and, 2) Determine the biological consequences of cross-reactivity in MIS-C. The scientific objective of this proposal is to elucidate specific mechanisms by which certain children, either by harboring pre-existing autoantibodies or generating cross-reactive adaptive immune responses, develop critical illness from common infections. The results will inform subsequent studies: a) establishing pathogenicity of these autoreactivities through organoid and murine models, b) building diagnostics to identify vulnerable children and targeted therapies to treat them, and c) translation of the immune profiling platform developed in this proposal into additional disease contexts.", "keywords": [ "2019-nCoV", "Address", "Adult", "Affinity", "Antibodies", "Antibody Formation", "Antigens", "Autoantibodies", "Autoantigens", "Autoimmune Diseases", "Autoimmune Process", "Automobile Driving", "B-Lymphocytes", "Bacteriophages", "Biochemical", "Biological", "Blood", "CD8-Positive T-Lymphocytes", "COVID-19", "COVID-19 pandemic", "COVID-19 pneumonia", "California", "Caring", "Cell Culture System", "Cell Line", "Cells", "Child", "Childhood", "Clinical", "Critical Care", "Critical Illness", "Cross Reactions", "Diagnostic", "Disease", "Enterovirus", "Epitopes", "Exhibits", "Exposure to", "Foundations", "Future", "Goals", "Immune", "Immune response", "Immunologics", "Immunoprecipitation", "In Vitro", "Individual", "Infection", "Inflammatory", "Influenza", "Insulin-Dependent Diabetes Mellitus", "Interferons", "Knowledge", "Laboratories", "Lead", "Life", "Link", "Longitudinal cohort", "Macrophage", "Maps", "Measurement", "Medicine", "Mentors", "Monoclonal Antibodies", "Multisystem Inflammatory Syndrome in Children", "Mutagenesis", "Nature", "Organoids", "Pathogenicity", "Pathologic", "Pathway interactions", "Patient Isolation", "Patients", "Pediatric Acute Respiratory Distress Syndrome", "Pediatrics", "Phenotype", "Physicians", "Positioning Attribute", "Program Development", "Property", "Protein Fragment", "Proteins", "Proteome", "Research", "Resolution", "SARS-CoV-2 antiviral", "SARS-CoV-2 infection", "Sampling", "San Francisco", "Scanning", "Scientist", "Symptoms", "System", "T cell response", "T-Cell Receptor", "T-Lymphocyte", "Technology", "Testing", "Tissues", "Training", "Translating", "Translations", "United States National Institutes of Health", "Universities", "Viral", "Work", "adaptive immune response", "adaptive immunity", "autoimmune pathogenesis", "autoreactivity", "career development", "cohort", "cross reactivity", "cytotoxicity", "disease phenotype", "experience", "experimental study", "functional genomics", "human disease", "improved outcome", "innovation", "mouse model", "novel", "pathogen", "pathogen exposure", "patient subsets", "pediatric patients", "professor", "response", "severe COVID-19", "skills", "systemic inflammatory response", "targeted treatment", "timeline" ], "approved": true } }, { "type": "Grant", "id": "15531", "attributes": { "award_id": "1R35NS137447-01", "title": "Expanding insights into FTD disease mechanisms", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 23658, "first_name": "FRANK PAUL", "last_name": "Shewmaker", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-12-15", "end_date": "2032-11-30", "award_amount": 1138538, "principal_investigator": { "id": 20546, "first_name": "LEONARD", "last_name": "PETRUCELLI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1414, "ror": "", "name": "MAYO CLINIC JACKSONVILLE", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1414, "ror": "", "name": "MAYO CLINIC JACKSONVILLE", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "Frontotemporal lobar degeneration (FTLD), which underlies frontotemporal dementia (FTD), encompasses a group of disorders with significant genetic, clinical, and neuropathological heterogeneity. FTLD is also genetically and pathologically associated with the motor neuron disease amyotrophic lateral sclerosis (ALS), with some patients developing both disorders. Understanding the diverse mechanisms governing FTLD pathogenesis is a fundamental area of interest of my research program, and we pursue this goal by asking impactful questions and applying innovative techniques. To accelerate scientific discovery, we have adopted a comprehensive approach that investigates multiple FTLD mechanisms driven by key molecular players like C9orf72, TDP-43, progranulin, tau and, more recently, TMEM106B. We also place great emphasis on translational research geared towards identifying much needed biomarkers and therapies, an area of particular importance given that there exists no treatment for FTLD. Since the funding of my current R35 at the end of 2016, my group has uncovered seminal findings related to the pathomechanisms mediated by FTLD-associated mutations in C9orf72 and GRN and shed crucial insight into the consequences of pathogenic TDP-43 and tau deposition in the brain. These findings have garnered high-impact publications in Science, Nature, and Cell and inspired new and ongoing avenues of research in my lab. The flexibility afforded by the R35 funding opportunity also allowed us to branch into other related topics and tackle urgent issues in the broader neuroscience field, including the need for biomarkers and mouse models for distinct repeat-associated disorders like spinocerebellar ataxias and the recent pressing need for tools to study and understand COVID-19 and its impact on the brain. Our productivity is influenced by the excellent research environment fostered at Mayo Clinic, which brings together highly interactive and devoted neurobiologists, geneticists, neuropathologists and physician scientists, the diversity of my team, and the numerous collaborations we have forged with world-renowned experts in the field, as well as our dedication to stewardship and the sharing of information and resources with the scientific community at large. Drawing from our past work on FTLD, we now propose to explore current cutting-edge questions related to: (1) the molecular underpinnings of TDP-43 localization and function and the downstream consequences of its dysfunction in disease, (2) the mechanisms underlying cryptic splicing in TDP-43 proteinopathies and the role of cryptic RNA and proteins in FTLD, (3) the role of the endo-lysosomal system in the development of TDP-43 pathology and neurodegeneration, and (4) the emerging role of TMEM106B fibrillogenesis in diverse neurodegenerative diseases including TDP-43 proteinopathies and tauopathies. We will use a combination of mouse and induced pluripotent stem-cell modeling, transcriptomics, proteomics, histology, and human tissue analyses to carry-out our proposed studies and address new and potentially transformative ideas as they emerge.", "keywords": [ "Acceleration", "Address", "Adopted", "Affect", "Amyotrophic Lateral Sclerosis", "Area", "Behavior", "Biological Markers", "Brain", "C9ORF72", "COVID-19", "Cells", "Clinic", "Clinical", "Collaborations", "Communities", "Dedications", "Deposition", "Development", "Disease", "Disease Progression", "Environment", "Fostering", "Frontotemporal Dementia", "Frontotemporal Lobar Degenerations", "Functional disorder", "Funding", "Funding Opportunities", "Genetic", "Goals", "Heterogeneity", "Histology", "Language", "Mediating", "Molecular", "Monitor", "Motor Neuron Disease", "Mus", "Mutation", "Nature", "Nerve Degeneration", "Neurodegenerative Disorders", "Neurosciences", "PGRN gene", "Pathogenesis", "Pathogenicity", "Pathologic", "Pathology", "Patients", "Personality", "Physicians", "Process", "Productivity", "Proteins", "Proteomics", "Publications", "RNA", "RNA Splicing", "Research", "Resources", "Role", "Science", "Scientist", "Seminal", "Spinocerebellar Ataxias", "System", "Tauopathies", "Techniques", "Translational Research", "Work", "fibrillogenesis", "flexibility", "forging", "human tissue", "improved", "induced pluripotent stem cell", "innovation", "insight", "interest", "mouse model", "neuropathology", "novel", "patient prognosis", "prevent", "programs", "protein TDP-43", "stem cell model", "tau Proteins", "tool", "transcriptomics" ], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1392, "count": 13920 } } }